Gilead’s Twice-Yearly PrEP Could Be ‘Transformative’ Therapy

Jul 17
Jul 17, 2025

In a first, the FDA recently approved a drug administered every six months as pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV. While some potential speed bumps to uptake exist, the therapy’s efficacy and less onerous dosing schedule compared with other similar medications could spur its use, making a tremendous difference in the fight against the infectious disease.

On June 18, the FDA approved Gilead Sciences, Inc.’s Yeztugo (lenacapavir) as PrEP to reduce the risk of sexually acquired HIV in adults and adolescents weighing at least 35 kg. A health care provider administers the medication via subcutaneous injection into the abdomen or thigh. With the initial injection, people also take two tablets of the medication on days one and two, and then subsequent dosing is an every-six-months injection.
Read more
© 2025 MMIT

Angela Maas

Angela has an extensive background of editing, reporting and writing for trade and consumer publications. She has written Radar on Specialty Pharmacy since she joined AIS Health in 2005 and has broad knowledge of the various issues at play within the space. She also has written for Spotlight on Market Access since its 2017 launch. Before joining AIS Health, she was managing editor at Employee Benefit News and Employee Benefit News Canada and managing editor at Hem Aware (a hemophilia publication), Lupus Living and Momentum (a multiple sclerosis publication). She has a B.A. in English and an M.A. in British literature from Arizona State University.